Skip to main content
SpringerLink
Log in

Das deutsche Forschungsnetz zu psychischen Erkrankungen

The German research network for mental disorders

  • Aktuelles
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Psychische Störungen gehören zu den großen medizinischen und gesellschaftlichen Herausforderungen, treten in allen Lebensabschnitten auf und zählen zu den wichtigsten Volkskrankheiten. In Deutschland leiden jedes Jahr 28 % der Bevölkerung unter psychischen Störungen; das Lebenszeitrisiko, an einer psychischen Störung zu erkranken, beträgt nahezu 50 %. Psychische Störungen verursachen großes Leid für die Betroffenen und ihr soziales Netzwerk. Sie sind aufgrund von verringerter Arbeitsproduktivität, Arbeitsausfall und Frühberentung mit der quantitativ größten Krankheitslast aller Krankheitsgruppen verbunden. Das Bundesministerium für Bildung und Forschung fördert von 2015 bis 2019 mit bis zu 35 Mio. Euro ein neues Forschungsnetz zu psychischen Erkrankungen, um über Grundlagenforschung und translationale klinische Forschung bessere Behandlungs- und Versorgungsstrategien zu entwickeln. Das aus einer kompetitiven Ausschreibung hervorgegangene Forschungsnetz zu psychischen Erkrankungen ist ein bundesweiter Zusammenschluss von neun Themenverbünden mit bis zu zehn Partnerinstitutionen psychiatrischer und klinisch-psychologischer, überwiegend universitärer Forschungseinrichtungen für Erwachsene bzw. für Kinder und Jugendliche. Zusätzlich wird auf drei verbundübergreifenden Querschnittsplattformen nach gemeinsamen Ursachen der Krankheitsentwicklung und neuen Möglichkeiten der Diagnostik von Angststörungen, Aufmerksamkeitsdefizit-Hyperaktivitäts-Störungen (ADHS), Autismus, bipolaren Störungen, Depressionen, Schizophrenie und psychotischen Störungen sowie Suchterkrankungen gesucht. Das Spektrum der untersuchten therapeutischen Ansätze reicht von innovativen pharmakologischen und psychotherapeutischen Therapien bis hin zu neuen Gehirnstimulationsverfahren. Eine nachhaltige Strukturförderung für psychische Erkrankungen ist künftig angesichts der hohen gesellschaftlichen Belastung dringend erforderlich. Das Netzwerk strebt an, Nukleus für eine nachhaltige Strukturförderung eines Deutschen Zentrums für psychische Erkrankungen zu werden.

Abstract

Mental disorders are among the greatest medical and social challenges facing us. They can occur at all stages of life and are among the most important commonly occurring diseases. In Germany 28 % of the population suffer from a mental disorder every year, while the lifetime risk of suffering from a mental disorder is almost 50 %. Mental disorders cause great suffering for those affected and their social network. Quantitatively speaking, they can be considered to be among those diseases creating the greatest burden for society due to reduced productivity, absence from work and premature retirement. The Federal Ministry of Education and Research is funding a new research network from 2015 to 2019 with up to 35 million euros to investigate mental disorders in order to devise and develop better therapeutic measures and strategies for this population by means of basic and translational clinical research. This is the result of a competitive call for research proposals entitled research network for mental diseases. It is a nationwide network of nine consortia with up to ten psychiatric and clinical psychology partner institutions from largely university-based research facilities for adults and/or children and adolescents. Furthermore, three cross-consortia platform projects will seek to identify shared causes of diseases and new diagnostic modalities for anxiety disorders, attention deficit hyperactivity disorders (ADHS), autism, bipolar disorders, depression, schizophrenia and psychotic disorders as well as substance-related and addictive disorders. The spectrum of therapeutic approaches to be examined ranges from innovative pharmacological and psychotherapeutic treatment to novel brain stimulation procedures. In light of the enormous burden such diseases represent for society as a whole, a sustainable improvement in the financial support for those researching mental disorders seems essential. This network aims to become a nucleus for long overdue and sustained support for a German center for mental disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Alzheimer’s Disease Neuroimaging Initiative ADNI. http://www.adni-info.org/. Zugegriffen: 18. Juli 2016

  2. Anagnostou E, Soorya L, Brian J, Dupuis A, Mankad D, Smile S et al (2014) Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res 1580:188–198

    Article  CAS  PubMed  Google Scholar 

  3. Anderson-Schmidt H, Adler L, Aly C, Anghelescu IG, Bauer M, Baumgärtner J et al (2013) The „DGPPN-cohort“: A national collaboration initiative by the German association for psychiatry and psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. Eur Arch Psychiatry Clin Neurosci 263(8):695–701

    Article  PubMed  Google Scholar 

  4. Arango C, Garibaldi G, Marder SR (2013) Pharmacological approaches to treating negative symptoms: A review of clinical trials. Schizophr Res 150(2-3):346–352

    Article  PubMed  Google Scholar 

  5. Aust S, Palm U, Padberg F, Bajbouj M (2015) Transcranial direct current stimulation for depressive disorders. Nervenarzt 86(12):1492–1499

    Article  CAS  PubMed  Google Scholar 

  6. Bajbouj M, Padberg F (2014) A perfect match: noninvasive brain stimulation and psychotherapy. Eur Arch Psychiatry Clin Neurosci 264(1):27–33

    Article  Google Scholar 

  7. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Bush AI (2008) N‑acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64(5):361–368

    Article  CAS  PubMed  Google Scholar 

  8. Bipolar Disorder Neuroimaging Database BiND. https://sites.google.com/site/bipolardatabase/. Zugegriffen: 18. Juli 2016

  9. Bouton ME (2002) Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biol Psychiatry 52:976–986

    Article  PubMed  Google Scholar 

  10. Brunoni AR, Valiengo L, Baccaro A, Zanão TA, de Oliveira JF, Goulart A et al (2013) The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry 70(4):383–391

    Article  CAS  PubMed  Google Scholar 

  11. Chang CK, Hayes RD, Perera G (2011) Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE 6:e19590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Collins et al (2011) Grand challenges in global mental health. Nature 475:27–30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cortese S et al (2013) Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 54(3):227–246

    Article  PubMed  Google Scholar 

  14. Craske M, Liao B, Brown L, Vervliet B (2012) Role of inhibition in exposure therapy. J Exp Psychopathol 3:322–245

    Article  Google Scholar 

  15. Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker AS (2008) Optimizing inhibitory learning during exposure therapy. Behav Res Ther 46(1):5–27

    Article  PubMed  Google Scholar 

  16. Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B (2014) Maximizing exposure therapy: an inhibitory learning approach. Behav Res Ther 58:10–23

    Article  PubMed  PubMed Central  Google Scholar 

  17. Cuthbert BN (2014) The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiat. Off J World Psychiatr Assoc 13:28–35

    Article  Google Scholar 

  18. Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015) Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 30(385):2190–2196

    Article  Google Scholar 

  19. Dawson G, Burner K (2011) Behavioral interventions in children and adolescents with autism spectrum disorder: a review of recent findings. Curr Opin Pediatr 23:616–620

    Article  PubMed  Google Scholar 

  20. Deacon BJ, Abramowitz JS (2004) Cognitive and behavioral treatments for AD. A review of meta-analytic findings. J Clin Psychol 60:429–441

    Article  PubMed  Google Scholar 

  21. Demiroglu SY, Skrowny D, Quade M, Schwanke J, Budde M, Gullatz V et al (2012) Managing sensitive phenotypic data and biomaterial in large-scale collaborative psychiatric genetic research projects: practical considerations. Mol Psychiat 17(12):1180–1185

    Article  CAS  Google Scholar 

  22. Deutsche Rentenversicherung (2013) Entwicklung der Anzahl der Frühberentungen wegen verminderter Erwerbsfähigkeit nach ausgewählten Diagnosegruppen. http://www.baua.de/de/Informationen-fuer-die-Praxis/Statistiken/Schwerpunkt/pdf/Psyche. Zugegriffen: 18. Juli 2016

    Google Scholar 

  23. Diekhof EK, Keil M, Obst KU, Henseler I, Dechent P, Falkai P et al (2012) A functional neuroimaging study assessing gender differences in the neural mechanisms underlying the ability to resist impulsive desires. Brain Res 14(1473):63–77

    Article  Google Scholar 

  24. Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, Grof P, Andreazza A et al (2014) Immunological and neurotrophic markers of risk status and illness development in high-risk youth: understanding the neurobiological underpinnings of bipolar disorder. Int J Bipolar Disord 2(1):29

    Article  PubMed  Google Scholar 

  25. Duits P, Cath DC, Lissek S, Hox JJ, Hamm AO, Engelhard IM et al (2015) Updated meta-analysis of classical fear conditioning in the anxiety disorders. Depress Anxiety 32(4):239–253

    Article  PubMed  Google Scholar 

  26. Faraone SV et al (2015) Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers Doi. doi:10.1038/nrdp.2015.20

    Google Scholar 

  27. Frazier TW (2012) Friends not foes: combined risperidone and behavior therapy for irritability in autism. J Am Acad Child Adolesct Psychiat 51:129–131

    Article  Google Scholar 

  28. Frye MA, McElroy SL, Fuentes M, Sutor B, Schak KM, Galardy CW et al (2015) Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses. Int J Bipolar Disord 3(1):30

    PubMed  Google Scholar 

  29. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L et al (2012) Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69(3):220–229

    Article  PubMed  Google Scholar 

  30. Grant BF, Hasin DS, Choux P, Stinson FS, Dawson DA (2004) Nicotine dependence and psychiatric disorders in the United States. Arch Gen Psychiatry 61:1107–1115

    Article  PubMed  Google Scholar 

  31. Grobe TG, Bitzer EM, Schwartz FW (2013) Barmer GEK Arztreport 2013 – Schwerpunktthema ADHS. BARMER GEK Arztreport 2013

  32. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E et al (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(10):718–779

    Article  CAS  PubMed  Google Scholar 

  33. Hägele C, Schlagenhauf F, Rapp MA, Sterzer P, Beck A, Bermpohl F et al (2015) Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. Psychopharmacology 232(2):331–341

    Article  PubMed  Google Scholar 

  34. Hasan A, Wobrock T, Palm U, Strube W, Padberg F, Falkai P et al (2015) Non-invasive brain stimulation for treatment of schizophrenic psychoses. Nervenarzt 86(12):1481–1491

    Article  CAS  PubMed  Google Scholar 

  35. Hasan A, Wobrock T, Grefkes C, Labusga M, Levold K, Schneider-Axmann T et al (2012) Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry 72(9):744–751

    Article  PubMed  Google Scholar 

  36. Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D et al (2005) Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 8:20–21

    Article  CAS  PubMed  Google Scholar 

  37. Heinz A, Schlagenhauf F (2010) Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 36(3):472–485

    Article  PubMed  PubMed Central  Google Scholar 

  38. Heinz AJ, Beck A, Meyer-Lindenberg A, Sterzer P, Heinz A (2011) Cognitive and neurobiological mechanisms of alcohol-related aggression. Nat Rev Neurosci 12(7):400–413

    Article  CAS  PubMed  Google Scholar 

  39. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S et al (2009) Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – Findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 43:215–229

    Article  PubMed  Google Scholar 

  40. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011) Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68(2):128–137

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hoagwood K, Olin SS (2002) The NIMH blueprint for change report. Research priorities in child and adolescent mental health. J Am Acad Child Adolesc Psychiatry 41:760–767

    Article  PubMed  Google Scholar 

  42. Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N et al (2016) Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 387:10023

    Article  Google Scholar 

  43. Human Connectome Project HCP. https://humanconnectome.org/. Zugegriffen: 18. Juli 2016

  44. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K et al (2010) Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167:748–751

    Article  PubMed  Google Scholar 

  45. Insel TR, Gogtay N (2014) National institute of mental health clinical trials: new opportunities, new expectations. JAMA Psychiatry 71:745

    Article  PubMed  Google Scholar 

  46. International Neuroimaging Data-sharing Initiative (INDI) http://fcon_1000.projects.nitrc.org/. Zugegriffen: 18. Juli 2016

  47. Jacobi F et al (2014) Mental disorders in the general population: Study on the health of adults in Germany and the additional module mental health (DEGS1-MH). Nervenarzt 85(1):77–87

    Article  CAS  PubMed  Google Scholar 

  48. Jacobi F, Höfler M, Siegert J, Mack S, Gerschler A, Scholl L et al (2014) Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH). Int J Methods Psychiatr Res 23(3):304–319

    Article  PubMed  Google Scholar 

  49. Jacobi F, Mack S, Gerschler A, Scholl L, Höfler M, Siegert J et al (2013) The design and methods of the mental health module in the German Health Interview and Examination Survey for Adults (DEGS1-MH). Int J Methods Psychiatr Res 22(2):83–99

    Article  PubMed  Google Scholar 

  50. Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N et al (2004) Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 34:597–611

    Article  CAS  PubMed  Google Scholar 

  51. Kamp-Becker I, Bölte S (2011) Autismus. Reinhardt, München

    Google Scholar 

  52. Keeser D, Meindl T, Bor J, Palm U, Pogarell O, Mulert C et al (2011) Prefrontal transcranial direct current stimulation changes connectivity of resting-state networks during fMRI. J Neurosci 31(43):15284–15293

    Article  CAS  PubMed  Google Scholar 

  53. Keown-Stoneman C, Horrocks J, Darlington GA, Goodday S, Grof P, Duffy A (2015) Multi-state models for investigating possible stages leading to bipolar disorder. Int J Bipol Disord 3:5

    Article  Google Scholar 

  54. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:593–602

    Article  PubMed  Google Scholar 

  55. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H‑U (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21(3):169–184

    Article  PubMed  PubMed Central  Google Scholar 

  56. Koutsouleris N, Ruhrmann S, Falkai P, Maier W (2013) Personalised medicine in psychiatry and psychotherapy. A review of the current state-of-the-art in the biomarker-based early recognition of psychoses. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(11):1522–1530

    Article  CAS  PubMed  Google Scholar 

  57. Kuo HI, Paulus W, Batsikadze G, Jamil A, Kuo MF, Nitsche MA (2015) Chronic enhancement of serotonin facilitates excitatory transcranial direct current stimulation-induced neuroplasticity. Neuropsychopharmacology 41:1223. doi:10.1038/npp.2015.270.

    Article  PubMed  Google Scholar 

  58. Lai HM, Cleary M, Sitharthan T, Hunt GE (2015) Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis. Drug Alcohol Depend 154:1–13

    Article  PubMed  Google Scholar 

  59. Lai M‑C, Lombardo MV, Baron-Cohen S (2014) Autism. Lancet 383:896–910

    Article  PubMed  Google Scholar 

  60. Lang T, Helbig-Lang S, Westphal D, Gloster AT, Wittchen HU (2011) Expositionsbasierte Therapie der Panikstörung mit Agoraphobie: Ein Behandlungsmanual. Hogrefe, Göttingen

    Google Scholar 

  61. Leopold K, Ratzer S, Correll CU, Rottmann-Wolf M, Pfeiffer S, Ritter P et al (2013) Characteristics, symptomatology and naturalistic treatment in individuals at-risk for bipolar disorders: Baseline results in the first 180 help-seeking individuals assessed at the Dresden high-risk project. J Affect Disord 152–154:427–433

    PubMed  Google Scholar 

  62. Leweke FM, Piomeli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94. doi:10.1038/tp.2012.15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M (2015) The suicide prevention effect of lithium: more than 20 years of evidence – a narrative review. Int J Bipol Disord 3:15

    Article  Google Scholar 

  64. Lissek S, Powers AS, McClure EB, Phelps EA, Woldehawariat G, Grillon C et al (2005) Classical fear conditioning in the anxiety disorders: a meta-analysis. Behav Res Ther 43(11):1391–1424

    Article  PubMed  Google Scholar 

  65. Mack S, Jacobi F, Gerschler A, Strehle J, Höfler M, Busch MA et al (2014) Self-reported utilization of mental health services in the adult German population – evidence for unmet needs? Results of the DEGS1-Mental Health Module (DEGS1-MH). Int J Methods Psychiatr Res 23(3):289–303

    Article  PubMed  Google Scholar 

  66. Major Depressive Disorder Neuroimaging Database (MaND) https://sites.google.com/site/depressiondatabase/. Zugegriffen: 18. Juli 2016

  67. Meyer TD, Hautzinger M (2013) Bipolare Störungen. Kognitive Verhaltenstherapie zur Rückfallprophylaxe. Beltz, Weinheim

    Google Scholar 

  68. Meyer-Lindenberg A (2012) The future of fMRI and genetics research. Neuroimage 62(2):1286–1292

    Article  CAS  PubMed  Google Scholar 

  69. Milad MR, Quirk GJ (2012) Fear extinction as a model for translational neuroscience: Ten years of progress. Ann Rev Psychol 63:129–151

    Article  Google Scholar 

  70. Neudeck P, Wittchen HU (2012) Exposure therapy. Rethinking the model – refining the method. Springer, New York

    Google Scholar 

  71. Nussbeck S, Skrowny D, O’Donoghue S, Schulze TG, Helbing K (2014) How to design biospecimen identifiers and integrate relevant functionalities into your biospecimen management system. Biopreserv Biobank 12(3):199–205

    Article  PubMed  PubMed Central  Google Scholar 

  72. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19:155–162

    Article  CAS  PubMed  Google Scholar 

  73. Pabst A, Kraus L, Gomes de Matos E, Piontek D (2013) Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 59(6):321–331

    Article  Google Scholar 

  74. Pajonk FG, Wobrock T, Gruber O, Scherk H, Berner D, Kaizl I et al (2010) Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 67(2):133–143

    Article  PubMed  Google Scholar 

  75. Pittig A, Stevens S, Vervliet B, Treanor M, Conway CC, Zbozinek T et al (2015) Optimierung expositionsbasierter Therapie. Psychotherapeut 60:401–418

    Article  Google Scholar 

  76. Pittig A, van den Berg Vervliet LB (2016) The key role of extinction learning in anxiety disorders: Behavioral strategies to enhance exposure-based treatments. Curr Opin Psychiatry 29(1):39–47

    Article  PubMed  Google Scholar 

  77. Plewnia C, Padberg F (2012) Transcranial and invasive brain stimulation for depression. Nervenarzt 83(8):1006–1012

    Article  CAS  PubMed  Google Scholar 

  78. Plewnia C, Schroeder P, Wolkenstein L (2015) Targeting the biased brain: noninvasive brain stimulation to ameliorate cognitive control. Lancet Psychiatry 2:351–356

    Article  PubMed  Google Scholar 

  79. Plewnia C, Zwissler B, Langst I, Maurer B, Giel K, Kruger R (2013) Effects of transcranial direct current stimulation (tDCS) on executive functions: Influence of COMT Val/Met polymorphism. Cortex 49(7):1801–1807

    Article  PubMed  Google Scholar 

  80. Polanczyk (2013) The burden of childhood mental disorders. Eur Child Adolesc Psychiatry 22:135–137

    Article  PubMed  Google Scholar 

  81. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948

    Article  PubMed  Google Scholar 

  82. Puls I, Mohr J, Wrase J, Vollstädt-Klein S, Leménager T, Vollmert C et al (2009) A model comparison of COMT effects on central processing of affective stimuli. Neuroimage 46(3):683–691

    Article  PubMed  Google Scholar 

  83. Rapp MA, Schnaider-Beeri M, Sano M, Silverman JM, Haroutunian V (2005) Cross-domain variability of cognitive performance in very old nursing home residents and community dwellers: relationship to functional status. Gerontology 51(3):206–212

    Article  PubMed  Google Scholar 

  84. Ruhrmann S, Klosterkötter J, Bodatsch M, Bechdolf A, Schimmelmann BG, Nikolaides A et al (2012) Pharmacological prevention and treatment in clinical at-risk states for psychosis. Curr Pharm Des 18(4):550–557

    Article  CAS  PubMed  Google Scholar 

  85. Schneider F, Falkai P, Maier W (2012) Psychiatrie 2020 plus. Perspektiven, Chancen und Herausforderungen, 2. Aufl. Springer, Berlin

    Book  Google Scholar 

  86. Schulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET et al (2010) The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the geneticbasis of response to lithium treatment. Neuropsychobiol 62(1):72–78

    Article  CAS  Google Scholar 

  87. Schulze TG (2010) Genetic research into bipolar disorder: the need for a research framework that integrates sophisticated molecular biology and clinically informed phenotype characterization. Psychiatr Clin North Am 33(1):67–82

    Article  PubMed  PubMed Central  Google Scholar 

  88. Schumann G, Binder EB, Holte A, de Kloet ER, Oedegaard KJ, Robbins TW (2014) Stratified medicine for mental disorders. Eur Neuropsychopharmacol 24(1):5–50

    Article  CAS  PubMed  Google Scholar 

  89. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M et al (2014) Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipol Disord 2:15

    Article  Google Scholar 

  90. Simon V, Czobor P, Balint S, Meszaros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194(3):204–211

    Article  PubMed  Google Scholar 

  91. Sinha R (2008) Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 1141:105–130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M et al (2013) Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 170(3):275–289

    Article  PubMed  Google Scholar 

  93. Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, Morgen K, Arnarsdottir S et al (2014) CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature 505(7483):361–366

    Article  CAS  PubMed  Google Scholar 

  94. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645

    Article  PubMed  Google Scholar 

  95. Van Praag HM, Asnis GM, Kahn RS, Brown SL, Korn M, Friedman JM et al (1990) Nosological tunnel vision in biological psychiatry. A plea for a functional psychopathology. Ann N Y Acad Sci 600:501–510

    Article  PubMed  Google Scholar 

  96. Veenstra-VanderWeele J, Blakely RD (2012) Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments. Neuropsychopharmacol 37(1):196–212

    Article  CAS  Google Scholar 

  97. Vervliet B, Craske MG, Hermans D (2013) Fear extinction and relapse: State of the art. J Exp Psychopathol 3:322–245

    Google Scholar 

  98. Wittchen HU (2012) The burden of mood disorders. Science 338(6103):15

    Article  CAS  PubMed  Google Scholar 

  99. Wittchen HU, Gloster AT (2009) Developments in the treatment and diagnosis of anxiety disorders. Psychiatr Clin North Am 32(3):xiii–xix

  100. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al (2011) The size and burden of mental disorders in Europe 2010. Eur Neuropsychopharmacol 21:655–679

    Article  CAS  PubMed  Google Scholar 

  101. Wolkenstein L, Zwick J, Hautzinger M, Joormann J (2014) Emotion regulation in euthymic bipolar disorder and remitted major depression. J Affect Disord 160:92–97

    Article  PubMed  Google Scholar 

  102. Wölwer W, Frommann N (2011) Social-cognitive remediation in schizophrenia: generalization of effects of the Training of Affect Recognition (TAR). Schizophr Bull 37(2):63–70

    Article  Google Scholar 

  103. Wölwer W, Frommann N, Halfmann S, Piaszek A, Streit M, Gaebel W (2005) Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. Schizophr Res 80(2–3):295–303

    Article  PubMed  Google Scholar 

  104. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2‑year randomized clinical trial. JAMA Psychiatry 70(9):913–920

    Article  PubMed  Google Scholar 

  105. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R et al (2007) Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 68(5):654–661

    Article  PubMed  Google Scholar 

  106. Wykes T, Haro JM, Belli SR, Obradors-Tarragó C, Arango C, Ayuso-Mateos JL et al (2015) Mental health research priorities for Europe. Lancet Psychiatry 2(11):1036–1042

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland

    M. Bauer

  2. Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland

    T. Banaschewski

  3. Klinik für Psychiatrie und Psychotherapie der Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin, Deutschland

    A. Heinz

  4. Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Marburg, Philipps-Universität Marburg, Marburg, Deutschland

    I. Kamp-Becker

  5. Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland

    A. Meyer-Lindenberg

  6. Klinik für Psychiatrie und Psychotherapie, Universität München, München, Deutschland

    F. Padberg

  7. Sozial- und Präventivmedizin, Exzellenzbereich Kognitionswissenschaften, Department Sport- und Gesundheitswissenschaften, Universität Potsdam, Potsdam, Deutschland

    M. A. Rapp

  8. Klinik für Psychiatrie und Psychotherapie, Bezirksklinikum Regensburg, Universität Regensburg, Regensburg, Deutschland

    R. Rupprecht

  9. Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Uniklinik RWTH Aachen, Aachen, Deutschland

    F. Schneider

  10. JARA-BRAIN Institut: Brain Structure Function Relationship, RWTH Aachen, Forschungszentrum Jülich GmbH, Jülich, Deutschland

    F. Schneider

  11. Institut für Psychiatrische Phänomik und Genomik (IPPG), Klinikum der Universität München, München, Deutschland

    T. G. Schulze

  12. Institut für Klinische Psychologie und Psychotherapie, Technische Universität Dresden, Dresden, Deutschland

    H.‑U. Wittchen

Authors
  1. M. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Banaschewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Heinz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Kamp-Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Meyer-Lindenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Padberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. A. Rapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Rupprecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T. G. Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H.‑U. Wittchen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Bauer.

Ethics declarations

Interessenkonflikt

A. Heinz, I. Kamp-Becker, A. Meyer-Lindenberg und F. Schneider geben an, dass kein Interessenkonflikt besteht. T. Banaschewski war innerhalb der letzten drei Jahre als Berater für die Firmen Actelion, Bristol-Myers Squibb, Hexal Pharma, Janssen-Cilag, Eli Lilly, Medice, Novartis, PCM Scientific, Shire, Yes-Pharma und Vifor Pharma tätig und hat Vortragshonorare von den Firmen Lilly, Janssen, McNeil, Medice, Novartis und Shire sowie Drittmittelförderung von den Firmen Shire und Vifor Pharma erhalten. Die vorliegende Publikation steht damit nicht im Zusammenhang. M. Bauer übte Beratertätigkeiten für AstraZeneca, Ferrer Int., Merz, Novartis, Janssen, Lilly, Lundbeck, Otsuka, Servier und Takeda aus und erhielt Vortragshonorare von AstraZeneca, Ferrer Int., Pfizer, Lilly, Lundbeck, Otsuka und Servier. Inhalte der vorliegenden Publikation stehen damit nicht im Zusammenhang. F. Padberg erhielt Honorare für Referententätigkeit von MAG & More GmbH sowie Unterstützung von der neuroConn GmbH und Brainsway Inc. für Forschungsvorhaben. M.A. Rapp hat in den letzten fünf Jahren bezahlte Vorträge und Beratungen für die folgenden Firmen durchgeführt: GlaxoSmithKline, Johnson & Johnson, Lilly, Merz, Willmar Schwabe. R. Rupprecht übt eine Beratertätigkeit für Grünenthal sowie Vortragstätigkeit für Servier aus. Ein Zusammenhang mit dem deutschen Forschungsnetz zu psychischen Erkrankungen sowie dem Inhalt des Manuskripts besteht diesbezüglich nicht. T.G. Schulze erhält finanzielle Unterstützung eines Forschungsprojekts von Roche. H.-U. Wittchen war oder ist Mitglied von Advisory Boards folgender Firmen: Lundbeck, Servier, Pfizer und Sanofi. Er hat ferner Projektzuwendungen für die Durchführung diverser epidemiologischer Studien der gleichen Firmen erhalten und ist Mitglied des Boards der Lundbeck Foundation (Dänemark) sowie Mitglied des THINC Steering Boards (Lundbeck).

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Caption Electronic Supplementary Material

115_2016_169_MOESM1_ESM.docx

Dokument 1: Neun Tabellen zur Struktur des Forschungsverbunds unterschiedlicher psychischer Erkrankungen sowie 2 Übersichtsabbildungen zu den Forschungsstandorten und den Querschnittsprojekten.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bauer, M., Banaschewski, T., Heinz, A. et al. Das deutsche Forschungsnetz zu psychischen Erkrankungen. Nervenarzt 87, 989–1010 (2016). https://doi.org/10.1007/s00115-016-0169-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-016-0169-y

Schlüsselwörter

Keywords

Search

Navigation